DBV Technologies DBV Technologies

VIASKIN technology VIASKIN® Technology

Diallertest product Diallertest® Products

Product Pipeline Product Pipeline

Media Room

24 November 2007

DBV Technologies and Numico (€2.6 billion of revenues in 2006) enter into an exclusive distribution agreement.

Paris, France - 24 November 2007 - Today DBV Technologies (DBV), a biopharmaceutical company engaged in the development of non-invasive epicutaneous delivery technology and products, and Numico announced an exclusive multi-annual promotion and distribution agreement for Diallertest® Milk, extending the original network, which covers France and certain overseas territories, to include the entire world. This partnership is part of the strategy of DBV Technologies to increase its international visibility.

The French company DBV Technologies has developed a unique globally patented technology, VIASKIN®*, with the backing of ANVAR, for the cutaneous administration of proteins and peptides. In June 2004, DBV Technologies released the first ready-to-use patch test for the diagnosis of delayed allergy to cow’s milk proteins, which is based on this unique technology: Diallertest® Milk.

Allergies are now a public health issue classified by WHO as the fourth global plague. In infants, cow’s milk protein allergy is the most frequently occurring and common food allergy. Causing a vast range of symptoms, this allergy is suffered painfully by children and their families alike since it is extremely difficult to diagnose. Diallertest® Milk was designed exclusively to diagnose cow’s milk protein allergy and is suitable for everyday medical practice. Practical, simple to use and painless, as it is completely non-invasive, and it can be applied directly by the parents to the child’s back at home. It significantly improves the efficacy in the diagnosis of cow’s milk protein allergy. The faster the diagnosis and treatment, the lower the risk of developing allergosis.

Since February 2006, Nutricia France, a subsidiary of Numico, a Dutch multinational specializing in the production and sale of nutritional foodstuffs, has distributed Diallertest® Milk in France. At present, around 70,000 Diallertest® Milk tests have already been prescribed nationally as well as in various countries such as Mexico and in the Middle East region.

Today, the new partnership with Numico will allow DBV Technologies to access a first-class international distribution network.

For Numico, this agreement is part of its new global strategy known as “act against allergy”: one of the focuses of the group’s work is the earlier diagnosis of a cow’s milk protein allergy in order to limit the risk of development of allergosis and to offer relevant products to newborn.

Thus Diallertest® Milk is an integral part of the development plans for Numico’s flagship product: Neocate®.

“We are delighted to enter into this significant partnership with Numico (€2.6 billion of consolidated revenues in 2006). This partnership allows us to position our first diagnostic product at a global level thanks to the support of a group leader in its specialist field and to push forward the development program of our allergy diagnosis and treatment product range, Diallertest® Milk”, Jean-François Biry, CEO comments.

“Diallertest® Milk fits perfectly with our portfolio of products for cow’s milk allergy. Numico is unique in being the only company to offer the full range of products for the management of cow’s milk allergy. Diallertest® Milk is the perfect diagnostic companion for these products and we are excited about the potential this product offers our business, Jonathan Wogel, GI / Allergy Business Unit Director comments.

* This technology was awarded the Siemens Prize for Innovation 2006.

-Ends-